Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia
暂无分享，去创建一个
[1] Anke Sparmann,et al. Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.
[2] T. Naoe,et al. BMI-1 is Highly Expressed in M0-Subtype Acute Myeloid Leukemia , 2005, International journal of hematology.
[3] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Sauvageau,et al. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells , 2003, Nature.
[5] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[6] T. Naoe,et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.
[7] W. Hiddemann,et al. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. , 1998, Blood.
[8] A. Kimura,et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. , 2006, Blood.